Share
Publications
-
12 April 2007 /Prices and reimbursement
Applications for individual reimbursement of medicinal products in 2006
In 2006, the Danish Medicines Agency reviewed some 106.700 applications for single reimbursement (down 4% on 2005), apporx. 14.600 applications for reimbursement for the chronically ill (down 37 % on 2005), approx. 9.200 applications for reimbursement for the terminally ill (same level as in 2005) and approx. 2.700 applications for increased reimbursement (same level as in 2005, cf. table 1 below).
-
12 February 2007 /Prices and reimbursement
Consumption of NSAID in 2005
In 2005, approximately 15 per cent of the Danish population bought NSAID on prescription (approximately 830.000 persons). This figure covers persons undergoing both long-term and short-term treatment, for example person with chronic arthritis diseases or persons with an isolated need, for instance in connection with sports injuries.
-
12 October 2006 /Prices and reimbursement
Consumption of antibiotics 2000 – 2005
The past years' development of the consumption of antibiotics has shown that the consumption has increased greatly for several broad-spectrum products. The reason for this may be the increasing extent of prescriptions of broad-spectrum products for infections not requiring such treatment.
-
31 July 2006 /Prices and reimbursement
Examination of single reimbursement for medicinal products
On behalf of Merck Sharp & Dohme (MSD), Tranberg Marketing Rekommandation has examined general practitioners' knowledge, experience and attitude to single reimbursement for medicine ("Praktiserende lægers kendskab, erfaring og holdning til enkelttilskud til medicin"). The examination is based on telephone interviews with 282 general practitioners.
-
06 June 2006 /Prices and reimbursement
-
02 June 2006 /Prices and reimbursement
Consumption of benzodiazepines and benzodiazepine related drugs (cyclopyrrolones)
During the 4th quarter 2003 it was decided that a range of initiatives were to be launched with the purpose of maintaining and strengthening the current tendency of a total decreasing consumption of benzodiazepines (sleeping medicine, tranquilisers and anti-anxiety agents) as well as cyclopyrrolones.
-
16 March 2006 /Prices and reimbursement
Changed consumption of hormones for menopausal women
The quantity consumption of hormones by women with menopausal discomfort has fallen drastically after announcements of increased risk of breast cancer. This is the finding of a consumption analysis performed by the Danish Medicines Agency on the basis of data from the Register of Medicinal Product Statistics.
-
23 February 2006 /Prices and reimbursement
Dose dispensing in the primary health sector - the last 6 months of 2005
During the first 6 months of 2005, approximately 26.000 people had their medicinal products dose dispensed. Elderly women constitute the main part of this group. The consumption of dose dispensed medicinal products amounts to 1.6 per cent of the total consumption of medicinal products during the first 6 months of 2005.
-
15 July 2005 /Prices and reimbursement
-
13 July 2005 /Prices and reimbursement
Sales of liberalised non-prescription medicinal products: 2001 - the first three months of 2005
For the main part of liberalised medicinal products, the liberalisation, and thereby the easier access to buy the medicinal products, has hardly affected the consumption development. One exception is the sale of anti-smoking products. Since the liberalisation on 1 October 2001, sales have increased by 48 per cent.
-
28 February 2005 /Prices and reimbursement
-
01 February 2005 /Prices and reimbursement
Potentially inappropriate prescription of the asthma product Singulair®
The asthma product Singulair® was put on the Danish market in February 1998 and became eligible for general reimbursement 13 July 1998. The medicinal product is recommended as a supplement for treatment of mild to moderate asthma as well as for exercise-induced asthma.
-
25 January 2005 /Prices and reimbursement
Consumption of antipsychotics in Denmark among the elderly
The Danish consumption of antipsychotics among elderly people aged 65 years or above is studied for the period 1996 and 1999-2003. The number of elderly people aged 65 years or above treated with antipsychotics has fallen, whereas the quantity consumption has risen.
-
29 October 2004 /Prices and reimbursement
Consumption of strong analgesics (opioids) in the primary sector Denmark 1999-2003
The study describes the development of the use of strong analgesics (opiods incl. codeine) from 1999 to 2003 in the primary sector. The quantity consumption of opiods has increased by 25.1 per cent during this period from 18.6 DDD/1.000 inhabitants/day in 1999 to 23.2 DDD/1.000 inhabitants/day in 2003.
-
29 October 2004 /Prices and reimbursement
Development of benzodiazepine consumption in Denmark 1996-2003
The benzodiazepine consumption has declined over many years, and this development continues in 2003. During the 8-year study period, the consumption of benzodiazepines as sleeping medicine and sedatives halved from 30.8 to 15.4 DDD/1.000 inhabitants/day
-
17 August 2004 /Prices and reimbursement
Treatment of blood clots with platelet function inhibitors
The rising expenses of platelet function inhibitors are caused by several factors. In general, the consumption of these medicinal products is increasing, which is due to the fact that, both in relative and absolute terms, more people start treatment with platelet function inhibitors.
-
06 July 2004 /Prices and reimbursement
Sale of medicinal products for the treatment of erectile dysfunction
This study sheds light on the development of the use of medicinal products for the treatment of erectile dysfunction in the period between 1998 and 2003. In october 1998, Viagra® was put on the market, and since then the sale of medicinal products for the treatment of erectile dysfunction has increased rapidly.
-
11 June 2004 /Prices and reimbursement
Consumption of antidepressants in Denmark in the primary health sector in the period 1994-2003
Antidepressant is the designation for medicinal products for depression. At some point in life, approxiamtely 15 per cent of the Danish population will be diagnosed with depression (The Danish Medicinal Product catalogue 2003) - women twice as often as men.
-
09 October 2003 /Prices and reimbursement
Note on products for Alzheimer's disease in Denmark
This study sheds light on the development of the use of medicinal products for Alzheimer's disease during the period September 1997 until April 2003. Four medicinal products are used for treating Alzheimer's disease - 3 cholinesterase inhibitors (Aricept®, Exelon® and Reminyl®) and a glutamine
-
30 September 2003 /Prices and reimbursement
The sale of the anti-cholinergic agent Spiriva®
Since Spiriva® was introduced on the market in the second quarter of 2002, there has been a great increase in both the consumption and prevalence of the agent among the elderly.
